• br Conclusions br Material and

  2023-09-09

  

  Conclusions Material and methods Conflicts of interest Acknowledgements Introduction Currently more than 30 human proteins are implicated in a range of degenerative disorders owing to their misfolding and misassembly into various aggregate structures and leading to at least 20 seriou

• br Conclusion We have identified

  2023-09-09

  

  Conclusion We have identified three non-competitive inhibitors of the human and porcine APN with Ki values in the μM range, by combining virtual screening and kinetic assays. Molecular docking simulations suggest these novel inhibitors block APN activity by an alternative mechanism to Zn coordina

• A characteristic of iron present in brain fluids

  2023-09-09

  

  A characteristic of iron present in brain fluids is considerable differences between measured values of ferritin and transferrin and the total iron content value (Table 1). Variation of the latter is compatible with differences in individual metabolisms. However differences between total iron conten

• AhR was proven to participate in carcinogenesis Its high

  2023-09-09

  

  AhR was proven to participate in carcinogenesis. Its high expression was demonstrated in a variety of tumors, i.e. pancreatic, prostate, urinary tract, lung and papillary thyroid carcinoma (Safe et al., 2013, Mian et al., 2014). However, cell line studies showed variable AhR levels/responses. AhR kn

• br Preliminary remarks Expression of

  2023-09-09

  

  Preliminary remarks Expression of the transcription factor aryl hydrocarbon receptor (AHR) and the AHR-repressor (AHRR) are both strikingly high in the 597 mg of barrier organs skin and gut [1,2]. It is generally assumed that this reflects their role in linking environmental factors to an adapted

• According to their structures and substrate specificity

  2023-09-09

  

  According to their structures and substrate specificity, MMPs are divided into five major groups: collagenases (e.g., MMP1), gelatinases (e.g., MMP2, MMP9), stromelysins (e.g., MMP3, MMP10), matrilysins (e.g., MMP7), and membrane-type MMPs [7]. Among them, MMP1 is a major collagenase that degrades t

• br Occurrence of Inosine in RNA Inosine

  2023-09-09

  

  Occurrence of Inosine in RNA Inosine is widespread among various types of RNAs including transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), long noncoding RNA (lncRNA), and microRNA (miRNA). Within these RNAs, inosine can appear in different locations as well. Table 1 lists examples

• Several reports of single cases of MG patients treated with

  2023-09-09

  

  Several reports of single cases of MG patients treated with Rituximab have claimed a favourable response (Baek et al., 2007, Gajra et al., 2004, Hain et al., 2006, Thakre et al., 2007, Wylam et al., 2003, Zaja et al., 2000). We report our experience with Rituximab in 6 patients with severe MG, 3 p

• Introduction Chronic inflammation is increasingly known

  2023-09-09

  

  Introduction Chronic inflammation is increasingly known as one of the most critical etiological factors in gastrointestinal (GI) cancers (Lee et al., 2016; Wang and Cho, 2015). Overexpression of 5-lipoxygenase (5-LOX), 5-LOX-activating protein (FLAP), as well as other leukotriene (LT) biosynthetic

• Our results clearly demonstrate that inhibition of ATM pathw

  2023-09-09

  

  Our results clearly demonstrate that inhibition of ATM pathway activation results in resistance to Vγ2Vδ2 T cell-mediated cell death. Therefore, enhancing ATM activation along with Vγ2Vδ2 T cell treatment would promote the cytotoxicity of resistant ovarian cancer cells. To our knowledge, this is the

• The finding of the apelin

  2023-09-08

  

  The finding of the apelin/APJ axis represents an impressive event in cardiovascular studies. As a result of various experimental and clinical studies conducted in vivo and in vitro, it has been indicated that apelin/APJ is a crucial mediator of cardiovascular homeostasis, which takes part in the pat

• br Conflict of interest br Acknowledgments This work was

  2023-09-08

  

  Conflict of interest Acknowledgments This work was financially supported by the Fund Project of Sichuan Provincial Department of Education (16ZB0053), the Scientific Research Foundation of Sichuan Agricultural University (No. 06021400) and the China Postdoctoral Science Foundation (No. 2015M58

• Nexturastat A Weak and transient interactions of HMGB protei

  2023-09-08

  

  Weak and transient interactions of HMGB proteins in such hit-and-run mechanisms are understandable given that “fluorescence loss in photobleaching” (FLIP) experiments employing GFP-labeled HMGBs have shown that in living cells they are the most mobile of all nuclear proteins [144]. The entire pool o

• Another class of AMPK regulator is peptidyl prolyl

  2023-09-08

  

  Another class of AMPK regulator is peptidyl-prolyl cis/trans isomerase (PPIase) NIMA-interacting 1 (Pin1), which binds to a number of proteins and regulates oncogenesis and metabolic diseases (Khanal et al., 2013; Zhou and Lu, 2016). Pin1 has been shown to bind to and inhibit AMPK; therefore, at lea

• MD was the recipient of

  2023-09-08

  

  MD was the recipient of the Intergroupe Francophone de Cancérologie Thoracique (IFCT) Alain Depierre Grant in 2014. JP was the recipient of the ARISTOT (Association de Recherche, d’Information Scientifique et Thérapeutique en Oncologie Thoracique) grant in 2016. Conflicts of interest statement

15583 records 285/1039 page Previous Next First page 上5页 281282283284285 下5页 Last page